Appetite stimulant with standard care for extensive small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether adding a drug that boosts appetite and weight to standard lung cancer treatment helps people with advanced small cell lung cancer who are experiencing weight loss and poor appetite. It aims to improve quality of life and treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with extensive-stage small cell lung cancer that has spread beyond one lung or to other parts of the body.
- You have not had chemotherapy for this stage of cancer before.
- You are experiencing signs of weight loss or poor appetite (pre-cachexia or cachexia).
- You have at least one tumor that can be measured by scans.
- You are physically able to perform daily activities (ECOG score 0-2) and expected to live at least 6 more months.
- You are not taking other appetite stimulants or certain steroids, and do not have conditions that affect your ability to eat or absorb food.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called megestrol acetate, which is a type of progesterone that can help increase appetite and reduce weight loss. It is for people with a certain type of lung cancer (small cell lung cancer) that has spread, especially if they are experiencing early signs of weight loss or frailty.
This study tests a new form of megestrol acetate (a medication that helps stimulate appetite and weight gain) for people with advanced liver cancer who are experiencing weight loss or loss of appetite. It is given alongside standard treatments for liver cancer, and the goal is to see if it can improve appetite and quality of life.
This trial tests a medicine called megestrol acetate (a type of hormone therapy) given after surgery to see if it helps improve appetite and weight in people with high-risk head and neck cancer. It is given alongside the usual radiation and chemotherapy treatment.
This study tests a medicine called nanocrystalline megestrol acetate to see if it can help improve appetite and promote weight gain in people with advanced non-small cell lung cancer who are losing weight. If you qualify, you would receive this treatment alongside your regular care to help you feel better and maintain your strength.
This study is testing whether a medication called megestrol acetate (a type of hormone that can boost appetite and help with weight gain) can improve outcomes for people with advanced non-small cell lung cancer who are malnourished. It is used as part of first-line treatment, meaning before any chemotherapy for the advanced cancer.
This trial tests whether adding a drug called nanocrystalline megestrol to standard chemotherapy and immunotherapy can help patients with extensive-stage small cell lung cancer who are losing weight or have poor appetite. It aims to improve nutrition and overall well-being during treatment.
Hear when a new Extensive-stage Small Cell Lung Cancer (ES-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.